Twenty-six years of HIV science: An overview of anti-HIV drugs metabolism

Brazilian Journal of Pharmaceutical Sciences

Volumn 47, Issue 2, 2011, Pages 209-230

  Andrade, Carolina Horta ^a   de Freitas, Lenis Medeiros ^a   de Oliveira, Valéria ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

AIDS treatment; Antiretroviral drugs; Biotransformation; Drugs anti HIV; Drugs metabolism

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD TOXICITY; COMPETITIVE INHIBITION; COMPUTER PREDICTION; DRUG ABSORPTION; DRUG CONJUGATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG SULFATION; DRUG TRANSFORMATION; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER METABOLISM; LIVER MICROSOME; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 84860392317     PISSN: 19848250     EISSN: 21759790     Source Type: Journal    
DOI: 10.1590/S1984-82502011000200003     Document Type: Review

References (127)

1. ABEL, S.; RUSSELL, D.; WHITLOCK, L.A.; RIDGEWAY, C.E.; NEDDERMAN, A.N.R.; WALKER, D.K. Assessment of the absorption, metabolism, and absolute bioavailability of maraviroc in healthy male subjects. Br. J. Clin. Pharmacol., v.65, suppl.1, p.60-67, 2008.
2. ADAMSON, C.S.; FREED, E.O. Anti-HIV-1 Therapeutics: from FDA-approved drugs to hypothetical future targets. Mol. Interv., v.9, p.70-74, 2009.
3. AFZELIUS, L.; ARNBY, C.H.; BROO, A.; CARLSSON, L.; ISAKSSON, C.; ULRIK JURVA, U.; KJELLANDER, B.; KOLMODIN, K.; NILSSON, K.; RAUBACHER, F.; WEIDOLF, L. State of the art tools for computational site of metabolism predictions: comparative analysis, mechanistically insights, and future applications. Drug Metab. Rev., v.39, p.61-86, 2007.
4. ANARI, M.R.; SANCHEZ, R.I.; BAKHTIAR, R.; FRANKLIN, R.B.; BAILLIE, T.A. Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: application to studies on the biotransformation of indinavir. Anal. Chem., v.76, p.823-832, 2004.
5. ANINAT, C.; PITON, A.; GLAISE, D.; LE CHARPENTIER, T.; LANGOUET, S.; MOREL, F.; Guguen-Guillouzo, C.; GUILLOUZO, A. Expression of cytochromes p450, conjugating enzymes and nuclear receptors in human hepatoma heparg cells. Drug Metab. Dispos., v.34, p.75-83, 2006.
6. ASHA S.; VIDYAVATHI, M. Cunninghamella - A microbial model for drug metabolism studies - A review. Biotechnol. Adv., v.27, p.16-29, 2009.
7. AZERAD, R. Microbial models for drug metabolism. Adv. Biochem. Eng. Biotechnol., v.63, p.163-218, 1999.
8. BALANI, S.K.; ARISON, B.H.; MATHAI, L.; KAUFFMAN, L.R.; MILLER, R.R.; STEARNS, R.A.; CHEN, I.W.; LIN, J.H. Metabolites of L-735, 524, a potent HIV 1-protease inhibitor, in human urine. Drug Metab. Dispos., v.23, p.266-270, 1995.
9. BALZARINI, J.; HOLÝ, A.; JINDRICH, J.; NAESENS, L.; SNOECK, R.; SCHOLS, D.; DE CLERCQ, E. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)- 2,6-diaminopurine. Antimicrob. Agents Chemother., v.37, p.332-338, 1993.
10. BALZARINI, J.; NAVE, J.F.; BECKER, M.A.; TATIBANA, M.; De Clerq, E. Kinetic properties of adenine nucleotide analogues against purified 5-phosphoribosyl-1- pyrophosphate synthetases from E. coli, rat liver and human erythrocytes. Nucleos. Nucleot. Nucl., v.14, p.1861-1871, 1995.
11. Barré-Sinoussi, F.; CHERMANN, J.C.; REY, F.; NUGEYRE, M.T.; CHAMARET, S.; GRUEST, J.; DAUGUET, C.; Axler-Blin, C.; Vézinet-Brun, F.; ROUZIOUX, C.; ROZENBAUM, W.; MONTAGNIER, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, v.220, p.868-871, 1983.
12. BRAGA, R.C.; TORRES, A.C.B.; PERSIANO, C.B.; ALVES, R.O.; FRAGA, C.A.M.; BARREIRO, E.J.; DE OLIVEIRA, V. Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LC-MS/MS: Application for a pharmacokinetic study. J. Pharm. Biomed. Anal., in press, 2011, DOI: 10.1016/j. jpba.2011.02.031.
13. BRUZZESE, V.L.; GILLUM, J.G.; ISRAEL, D.S.; JOHNSON, G.L.; KAPLOWITZ, L. G.; POLK, R.E. Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus. Antimicrob. Agents Chemother., v.39, p.1050-1053, 1995.
14. BUMPUS, N.N.; KENT, U.M.; HOLLENBERG, P.F. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J. Pharmacol. Exp. Ther., v.318, p.345-351, 2006.
15. CANAVAN, N. FDA and drug companies alike want ADME-tox testing performed earlier and earlier in a drug's life cycle. Drug Discov. Dev., v.10, p.34-36, 2007.
16. CARNEIRO, E.O.; MENEGATTI, R.; FRAGA, C.A.M.; BARREIRO, E.J.; DE OLIVEIRA, V. Microbial models of animal metabolism: application to a study of the metabolism of LASSBio-873. Braz. J. Pharm. Sci., v.41, p.392-392, 2005.
17. CARNEIRO, E.O.; ANDRADE, C.H.; BRAGA, R.C.; TÔRRES, A.C.B., ALVES, R.O.; LIÃO, L.M.; FRAGA, C.A.M.; BARREIRO, E.J.; De Oliveira, V. Structure-based prediction and biosynthesis of the major mammalian metabolite of the cardioactive prototype LASSBio-294. Bioorg. Med. Chem. Lett., v.20, p.3734-3736, 2010.
18. CHANG, M.; SOOD, V.K.; KLOOSTERMAN, D.A.; HAUER, M.J.; FAGERNESS, P. E.; SANDERS, P.E.; VRBANAC, J.J. Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys. Drug Metab. Dispos., v.25, p.814-827, 1997a.
19. CHANG, M.; SOOD, V.K.; WILSON, G.J.; KLOOSTERMAN, D.A.; SANDERS, P.E.; HAUER, M.J.; ZHANG, W.; BRANSTETTER, D.G. Metabolism of the HIV-1 Reverse transcriptase inhibitor delavirdine in mice. Drug Metab. Dispos., v.25, p.828-839, 1997b.
20. CHANG, M.; SOOD, V.K.; WILSON, G.J.; KLOOSTERMAN, D.A.; SANDERS, P. E.; HAUER, M.J.; FAGERNESS, P.E. Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats. Drug Metab. Dispos., v.25, p.228-242, 1997c.
21. CHIBA, M.; HENSLEIGH, M.; LIN, J.H. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes: Major role of CYP3A. Biochem. Pharmacol., v.53, p.1187-1195, 1997.
22. CHIBA, M.; HENSLEIGH, M.; NISHIME, J.A.; BALANI, S.K.; LIN, J.H. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos., v.24, p.307-314, 1996.
23. CHIBA, M.; NISHIME, J.A.; NEWAY, W.; LIN, Y.; LIN, J.H. Comparative in vitro metabolism of indinavir in primates - a unique stereoselective hydroxylation in monkey. Xenobiotica, v.30, p.117-129, 2000.
24. CHIU, T.K.; DAVIES, D.R. Structure and function of HIV-1 integrase. Curr.Top. Med. Chem., v.4, p.965-77, 2004.
25. COHEN M.S.; HELLMANN, N.; LEVY, J.A.; DECOCK, K.; LANGE, J. The spread, treatment, and prevention of HIV- 1: evolution of a global pandemic. J. Clin. Invest., v.118, p.1244-1254, 2008.
26. COLLINS, J.M. Inter-species differences in drug properties. Chem. Biol. Interact., v.134, p.237-242, 2001.
27. COOPER, D.A.; STEIGBIGEL, R.T.; GATELL, J.M.; ROCKSTROH, J.K.; KATLAMA, C.; YENI, P.; LAZZARIN, A.; CLOTET, B.; KUMAR, P.N.; ERON, J.E.; SCHECHTER, M.; MARKOWITZ, M.; LOUTFY, M.R.; LENNOX, J.L.; ZHAO, J.; CHEN, J.; RYAN, D.M.; RHODES, R.R.; KILLAR, J.A.; GILDE, L.R.; STROHMAIER, K.M.; MEIBOHM, A.R.; MILLER, M.D.; HAZUDA, D.J.; NESSLY, M.L.; DINUBILE, M.J.; ISAACS, R.D.; TEPPLER, H.; NGUYEN, B.Y. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med., v.359, p.355-365, 2008.
28. COSTA, E.M.M.B.; PIMENTA, F.C.; LUZ, W.C.; De Oliveira V. Selection of filamentous fungi of the Beauveria genus able to metabolize quercetin like mammalian cells. Braz. J. Microbiol., v.39, p.405-408, 2008.
29. COURT, M.H.; KRISHNASWAMY, S.; HAO, Q.; DUAN, S.X.; PATTEN, C.J.; VON MOLTKE, L.L.; GREENBLATT, D.J. Evaluation of 3_-azido-3_-deoxythymidine, morphine and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab. Dispos., v.31, p.1125-1133, 2003.
30. CRETTON, E.M.; SCHINAZI, R.F.; MCCLURE, H.M.; ANDERSON, D.C.; SOMMADOSSI, J.P. Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys. Antimicrob. Agents Chemother., v.35, p.801-807, 1991.
31. CRETTON, E.M.; ZHOU, Z.; KIDD, L.B.; MCCLURE, H.M.; KAUL, S.; HITCHCOCK, M.J.; SOMMADOSSI, J.P. In vitro and in vivo disposition and metabolism of 3'-deoxy- 2',3'-didehydrothymidine. Antimicrob. Agents Chemother., v.37, p.1816-1825, 1993.
32. CRUCIANI, G.; CAROSATI, E.; DEBOECK, B.; ETHIRAJULU, K.; MACKIE, C.; HOWE, T.; VIANELLO, R. MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J. Med. Chem., v.48, p.6970-6979, 2005.
33. DARVAS F. Predicting metabolic pathways by logic programming. J. Mol. Graph., v.6, p.80-86, 1988.
34. De Clercq, E. Anti-HIV drugs. Verh. K. Acad. Geneesk. Belg., v.64, p.81-104, 2007.
35. De Clercq, E. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections. Expert Rev. Anti-Infect. Ther., v.1, p.21-43, 2003.
36. DE GRAFF, C.; VERMEULEN, N.P.E.; FEENSTRA, K.A. Cytochrome P450 in silico: an integrative modeling approach. J. Med. Chem., v.48, p.2725-2755, 2005.
37. DECKER, C.J.; LAITINEN, L.M.; BRIDSON, G.W.; RAYBUCK, S.A.; TUNG, R.D.; CHATURVEDI, P.R. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J. Pharm. Sci., v.87, 803-807, 1998.
38. DENISSEN, J.F.; GRABOWSKI, B.A.; JOHNSON, M.K.; BUKO, A.M.; KEMPF, D. J.; THOMAS, S.B.; SURBER, B.W. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab. Dispos., v.25, p.489-501, 1997.
39. DIAS, L.E.S.; ANDRADE, C.H.; PAZINI, F.; DE OLIVEIRA, V. Preparation of new metabolites from lamivudine by filamentous fungi bioconversion. Braz. J. Pharm. Sci., v.41, p.133-133, 2005.
40. DORR, P.; WESTBY, M.; DOBBS, S.; GRIFFIN, P.; IRVINE, B.; MACARTNEY, M.; MORI, J.; RICKETT, G.; Smith-Burchnell, C.; NAPIER, C.; WEBSTER, R.; ARMOUR, D.; PRICE, D.; STAMMEN, B.; WOOD, A.; PERROS, M. Maraviroc (UK-427 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother., v.49, p.4721-4732, 2005.
41. EAGLINGS, V.A.; WILTSHIRE, H.; WHITCOMBE, I.W.A.; BACK, D.J. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica, v.32, p.1-17, 2002.
42. EKINS, S.; ANDREYEV, S.; RYABOV, A.; KIRILLOV, E.; RAKHMATULIN, E.A.; SOROKINA, S.; BUGRIM, A.; NIKOLSKAYA, T. A combined approach to drug metabolism and toxicity assessment. Drug Metab. Dispos., v.34, p.495-503, 2006.
43. ERICKSON, D.A.; MATHER, G.; TRAGER, W.F.; LEVY, R.H.; KEIRNS, J.J. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab. Dispos., v.27, p.1488-1495, 1999.
44. FALETTO, M.B.; MILLER, W.H.; GARVEY, E.P.; St. CLAIRE, M.H.; DALUGE, S. M.; GOOD, S.S. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother., v.41, p.1099-1107, 1997.
45. FAUCI, A.S. HIV and AIDS: 20 years of science. Nat. Med., v.9, p.839-843, 2003.
46. FERRAIOLO, B.L.; MOHLER, M.A.; GLOFF, C.A. Goals and analytical methodologies for protein disposition studies. In: FERRAIOLO, B.L.; MOHLER, M.A.; GLOFF, C.A. Protein pharmacokinetics and metabolism. New York: Plenum Press. 1992. p.1-21.
47. FITZSIMMONS, M.E.; COLLINS, J.M. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small intestinal cytochrome P450 3A4: Potential contribution to high first-pass metabolism. Drug Metab. Dispos., v.25, p.256-266, 1997.
48. FLETCHER, C.V. Enfuvirtide, a new drug for HIV infection. Lancet, v.361, p.1577-78, 2003.
49. FREITAS, L.M. Avaliação do perfil metabólico da estavudina através do emprego da bioconversão e da modelagem molecular do citocromo P-450 CYP3A4. Goiânia, 2009. 173 p. [Dissertação de Mestrado. Faculdade de Farmácia. Universidade Federal de Goiás].
50. FURMAN, P.A.; FYFE, J.A.; St. CLAIR, M.H.; WEINHOLD, K.; RIDEOUT, J.L.; FREEMAN, G.A.; Nusinoff-Lehrman, S.; BOLOGNESI, D.P.; BRODER, S.; MITSUYA, H.; BARRY, D.W. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA, v.83, p.8333-8337, 1986.
51. GOMES, T.C.F.; ANDRADE, C.H.; CIRILO, H.N.C.; RIOS, D.P.; DIAS, L.E.S.; PAZINI, F.; DE OLIVEIRA, V. Bioconversão de antiretrovirais por Cunninghamella echinulata ATCC 9244. In: ENCUENTRO REGIONAL BIOCATÁLISIS Y BIOTRANSFORMACIONES, 2., 2006, São Paulo. Resumos. São Paulo: Instituto de Química da Universidade de São Paulo, 2006. p.51-51.
52. Gomez-Lechon, M.J.; DONATO, M.T.; CASTELL, J.V.; JOVER, R. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr. Drug Metab., v.5, p.443-462, 2004.
53. GOOD, S.S.; DALUGE, S.M.; CHING, S.V.; AYERS, M.M.; MAHONY, W.B.; FALETTO, M.B.; DOMIN, B.A.; OWENS, B.S.; DORNSIFE, R.E., MCDOWELL, J.A.; LAFON, S.W.; SYMONDS, W.T. 1592U89 succinate-preclinical toxicological and disposition studies and preliminary clinical pharmacokinetics. Antiviral Res., v.26, p.A229, 1995.
54. GRINSZTEJN, B.; NGUYEN, B.Y.; KATLAMA, C.; GATELL, J.M.; LAZZARIN, A.; VITTECOQ, D.; GONZALEZ, C.J.; CHEN, J.; HARVEY, C.M.; ISAACS, R.D. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK- 0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet, v.369, p.1261-1269, 2007.
55. GUENGERICH, F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS Journal, v.8, p.E101-E111, 2006.
56. HAMMER, S.M.; SAAG, M.S.; SCHECHTER, M.; MONTANER, J.S.; SCHOOLEY, R.T.; JACOBSEN, D.M.; THOMPSON, M.A.; CARPENTER, C.C.; FISCHL, M.A.; GAZZARD, B.G.; GATELL, J.M.; HIRSCH, M.S.; KATZENSTEIN, D.A.; RICHMAN, D.D.; VELLA, S.; YENI, P.G.; VOLBERDING, P.A. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. JAMA, v.296, p.827-843, 2006.
57. HESSE, L.M.; VON MOLTKE, L.L.; SHADER, R.I.; GREENBLATT, D.J. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab. Dispos., v.29, p.100-102, 2001.
58. HIRANI, V N.; RAUCY, J.L.; LASKER, J.M. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Drug Metab. Dispos., v.32, p.1462-1467, 2004.
59. HORWITZ, J.P.; CHUA, J.; NOEL, M. Nucleosides V. Monomethanesulfonates of 1-(2-deoxy-b-D-threo-pentofuranosyl)thymine. J. Org. Chem., v.29, 2076-2078, 1964.
60. HYLAND, R.; DICKINS, M.; COLLINS, C.; JONES H.; JONES, B. Maraviroc: in vitro assessment of drug-drug interaction potential. Br. J. Clin. Pharmacol., v.66, suppl.4, p.498-507, 2008.
61. IWAMOTO, M.; KASSAHUN, K.; TROYER, M.D.; HANLEY, W.D.; LU, P.; RHOTON, A.; PETRY, A.S.; GHOSH, K.; MANGIN, E.; DENOIA, E.P.; WENNING, L.A.; STONE, J.A.; GOTTESDIENER, K.M.; WAGNER, J.A. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/ in vivo correlation. J. Clin. Pharmacol., v.48, p.209-214, 2008.
62. JOHNSON, M.A.; HORAK, J.; BREUEL, P. The pharmacokinetics of iamivudine in patients with impaired hepatic function. Eur. J. Clin. Pharmacol., v.54, p.363-366, 1998.
63. KASSAHUN, K.; MCINTOSH, I.; CUI, D.; HRENIUK, D.; MERSCHMAN, S.; LASSETER, K.; AZROLAN, N.; IWAMOTO, M.; WAGNER J.A.; WENNING, L.A. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos., v.35, p.1657-1663, 2007.
64. KAUL, S.; SHYU, W.C.; SHUKLA, U.A.; DANDEKAR, K.A.; BARBHAIYA, R.H. Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog. Drug Metab. Dispos., v.21, p.447-453, 1993.
65. KHALIQ, Y.; GALLICANO, K.; SEGUIN, I.; FYKE, K.; CARIGNAN, G.; BULMAN, D.; BADLEY, A.; CAMERON, D.W. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Br. J. Clin. Pharmacol., v.50, p.108-115, 2000.
66. KLOPMAN, G.; DIMAYUGA, M.; TALAFOUS, J. META A program for the evaluation of metabolic transformation of chemicals. J. Chem. Inf. Comput. Sci., v.34, p.1320-1325, 1994.
67. KRUSZEWSKA, H.; CHMIELOWIEC, U.; BEDNAREK, E.; Witowska-Jarosz, J.; DOBROWOLSKI, J.C.; MISICKA, A. Spectroscopic identification of AZT derivative obtained from biotransformation of AZT by Stenotrophomonas maltophilia. J. Mol. Struct., v.651-653, p.645-650, 2003.
68. KUMAR, G.N.; DYKSTRA, J.; ROBERTS, E.M.; JAYANTI, V.K.; HICKMAN, D.; UCHIC, J.; YAO, Y.; SURBER, B.; THOMAS, S.; GRANNEMAN, G.R. Potent Inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab. Dispos., v.27, p.902-908, 1999.
69. KUMAR, G.N.; RODRIGUES, A.D.; BUKO, A.M.; DENISSEN, J.F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther., v.277, p.423-431, 1996.
70. KUMAR, G.N.; SURAPANENI, S. Role of drug metabolism in drug discovery and development. Med. Res. Rev., v.21, p.397-411, 2001.
71. LAZZARIN, A.; CAMPBELL, T.; CLOTET, B.; JOHNSON, M.; KATLAMA, C.; MOLL, A.; TOWNER, W.; TROTTIER, B.; PEETERS, M.; VINGERHOETS, J.; DE SMEDT, G.; BAETEN, B.; BEETS, G.; SINHA, R.; WOODFALL, B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, v.370, p.39-48, 2007.
72. LE VEE, M.; JIGOREL, E.; GLAISE, D.; GRIPON, P.; Guguen-Guillouzo, C.; FARDEL, O. Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur. J. Pharm. Sci., v.28, p.109-117, 2006.
73. LEE, J.S.; OBACH, R.S.; FISHER, M.B. Drug metabolizing enzymes. Cytochrome P450 and other enzymes in drug discovery and development. New York: Marcel Dekker, Inc., 2003. 587 p.
74. LI, A.P.; MAUREL, P.; Gomez-Lechon, M.J.; CHENG, L.C.; Jurima-Romet, M. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem. Biol. Interact., v.107, p.5-16, 1997.
75. LI, X.; CHAN, W.K. Transport, metabolism and elimination mechanisms of anti-HIV agents. Adv. Drug Delivery Rev., v.39, p.81-103, 1999.
76. LILLIBRIDGE, J.H.; LIANG, B.H.; KERR, B.M.; WEBBER, S.; QUART, B.; SHETTY, B.V.; LEE, C.A. Characterization of the selectivity and mechanism of human cytochrome P450 Inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab. Dispos., v.26, p.609-616, 1998.
77. LIN, J.H.; CHIBA, M.; BALANI, S.K.; CHEN, I. W.; KWEI, G.Y.; VASTAG, K.J.; NISHIME, J.A. Species differences in the pharmacokinetics and metabolism of indinavir, a potent HIV protease inhibitor. Drug Metab. Dispos., v.24, p.1111-1120, 1996.
78. MACKENZIE, P.I.; OWENS, I.S.; BURCHELL, B.; BOCK, K.W.; BAIROCH, A.; BÉLANGER, A.; Fournel-Gigleux, S.; GREEN, M.; HUM, D.W.; IYANAGI, T.; LANCET, D.; LOUISOT, P.; MAGDALOU, J.; CHOWDHURY, J.R.; RITTER, J.K.; SCHACHTER, H.; TEPHLY, T.R.; TIPTON, K.F.; NEBERT, D.W. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenet., v.7, p.255-269, 1997.
79. MADRUGA, J.V.; CAHN, P.; GRINSZTEJN, B.; HAUBRICH, R.; LALEZARI, J.; MILLS, A.; PIALOUX, G.; WILKIN, T.; PEETERS, M.; VINGERHOETS, J.; DE SMEDT, G.; LEOPOLD, L.; TREFIGLIO, R.; WOODFALL, B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, v.370, p.29-38, 2007.
80. MATTHEWS, T.; SALGO, M.; GREENBERG, M.; CHUNG, J.; DEMASI, R.; BOLOGNESI, D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov., v.3, p.215-225, 2004.
81. MCDOWELL, J.A.; CHITTICK, G.E.; RAVITCH, J.R.; POLK, R.E.; KERKERING, T.M.; STEIN, D.S. Pharmacokinetics of [14C]Abacavir, a human immunodeficiency Virus Type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob. Agents Chemother., v.43, p.2855-2861, 1999.
82. MEHELLOU, W.; DE CLERCQ, E. Twenty-six years of anti- HIV drug discovery: where do we stand and where do we go? J. Med. Chem., v.53, p.521-538, 2010.
83. MEIJER, D.K.F.; SWART, P.J. Isolated perfused liver as a tool to study the disposition of peptides, liver first-pass effects, and cell-specific drug delivery. J. Controlled Release, v.46, p.139-156, 1997.
84. MERCK & CO., Inc. Raltegravir tablets FDA Advis. Comm. Meet. Briefing Document (Background Package), Whitehouse Station, NJ: Merck & Co, Inc; 2007. p.19.
85. MERTA, A.; VOTRUBA, I.; JINDRICH, J.; HOLÝ, A.; CIHLÁR, T.; ROSENBERG, I.; OTMAR, M.; HERVE, T.Y. Phosphorylation of 9-(2-phosphonomethoxyethyl) adenine and 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine by AMP (dAMP) kinase from L1210 cells. Biochem. Pharmacol., v.44, p.2067-2077, 1992.
86. MITSUYA, H.; WEINHOLD, K.J.; FURMAN, P.A.; ST CLAIR, M.H.; LEHRMAN, S.N.; GALLO, R.C.; BOLOGNESI, D.; BARRY, D.W.; BRODER, S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy associated virus in vitro. Proc. Natl. Acad. Sci. USA, v.82, p.7096-7100, 1985.
87. MODA, T.L.; TORRES, L.G.; CARRARA, A.E.; ANDRICOPULO, A.D. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models. Bioinformatics, v.24, p.2270-2271, 2008.
88. MOULY, S.; LOWN, K.S.; KORNHAUSER, D.; JOSEPH, J.L.; FISKE, W.D.; BENEDEK, I.H.; WATKINS, P.B. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Therap., v.72, p.1-9, 2002.
89. MUTLIB, A.E.; CHEN, H.; NEMETH, G.A.; MARWALDER, J.A.; SEITZ, S.P.; GAN, L.S.; CHRIST, D.D. Identification and characterization of efavirenz metabolites by LC/MS and high field NMR. Species differences in the metabolism of efavirenz. Drug Metab. Dispos., v.27, p.1319-1333, 1999.
90. NARITOMI, Y.; TERASHITA, S.; KAGAYAMA, A.; SUGIYAMA, Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab. Dispos., v.31, p.580-588, 2003.
91. NAVÉ, J.F.; ESCHBACH, A.; Wolff-Kugel, D.; HALAZY, S.; BALZARINI, J. Enzymatic phosphorylation and pyrophosphorylation of 2',3'-dideoxyadenosine-5'- monophosphate, a key metabolite in the pathway for activation of the anti-HIV (human immunodeficiency virus) agent 2',3'-dideoxyinosine. Biochem. Pharmacol., v.48, p.1105-1112, 1994.
92. NUNES, E.S. Aplicação da bioconversão da zidovudina por Cunninghamella echinulata ATCC 9244 na síntese de derivados funcionalizados por carboidratos. Goiânia, 2008. 146 p. [Dissertação de Mestrado. Faculdade de Farmácia. Universidade Federal de Goiás].
93. OMURA, T. Forty years of cytochrome P450. Biochem. Biophys. Res. Commun., v.266, p.690-698, 1999.
94. PAZINI, F.; DE OLIVEIRA, V.; MENEGATTI, R.; FIGUEIRA, A.P.; FRAGA, C.A.M.; BARREIRO, E.J. Preparação de metabólitos fase I e II do derivado N-fenilpiperazínico (LASSBio-581) via bioconversão por Cunninghamella echinulata ATCC 9244 e Mortierella isabelina NRRL 1757. Rev. Eletr. Farm., v.2, supl.2, p.157-160, 2005.
95. PAZINI, F.; MENEGATTI, R.; SABINO, J.R.; ANDRADE, C.H.; NEVES, G.; RATES, S. M.K.; NOËL, F.; FRAGA, C.A.M.; BARREIRO, E.J.; DE OLIVEIRA, V. Design of new dopamine D2 receptor ligands: Biosynthesis and pharmacological evaluation of the hydroxylated metabolite of LASSBio-581. Bioorg. Med. Chem. Lett., v.20, p.2888-2891, 2010.
96. PELKONEN, O.; TURPEINEN, M.; UUSITALO, J.; RAUTIO, A.; RAUNIO, H. Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin. Pharmacol. Toxicol., v.96, p.167-175, 2005.
97. PERROS, M. CCR5 antagonists for the treatment of HIV infection and AIDS. Adv. Antiviral Drug Design, v.5, p.185-212, 2007.
98. PRAKASH, C.; VAZ, A.D.N. Drug metabolism: significance and challenges. In: XIE, W. (Ed.). Nuclear receptors in drug metabolism. New York: John Wiley & Sons, Inc. 2009. Chap.1, p.1-41.
99. RAMANATHAN, S.; SHEN, G.; CHENG, A.; KEARNEY, B.P. Pharmacokinetics of emtricitabine, tenofovir, and GS- 9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavirboosted GS-9137. J. Acquir. Immune Defic. Syndr., v.45, p.274-279, 2007a.
100. RAMANATHAN, S.; WRIGHT, M.; WEST, S.; KEARNEY, B.P. Pharmacokinetics, metabolism and excretion of ritonavir-boosted GS-9137 (elvitegravir). In: INTERNATIONAL WORKSHOP ON CLINICAL PHARMACOLOGY OF HIV THERAPY, 8., Budapest, Hungary, 2007. Abstract. Budapest: 2007b. p.30-31.
101. RAVITCH, J.R.; BRYANT, B.J.; REESE, M.J.; BOEHLERT, C.C.; WALSH, J.S.; MCDOWELL, J.P.; SADLER, B.M. CNS penetration of the anti-retroviral 1592 in human and animal models. In: CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, 5., 1998, Chicago, Ill. Abstract. Chicago: Foundation for Retrovirology and Human Health, 1998. p.199-199.
102. RISKA, P.; LAMSON, M.; MCGREGOR, T.; SABO, J.; HATTOX, S.; PAV, J.; KEIRNS, J. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Dispos., v.27, p.895-901, 1999a.
103. RISKA, P.S.; JOSEPH, D.P.; DINALLO, R.M.; DAVIDSON, W.C.; KEIRNS, J.J.; HATTOX, S.E. Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees. Drug Metab. Dispos., v.27, p.1434-1447, 1999b.
104. Rodriguez-Novoa, S.; BARREIRO, P.; RENDÓN, A.; Jiménez-Nacher, I.; González-Lahoz, J.; SORIANO, V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin. Infect. Dis., v.40, p.1358-1361, 2005.
105. SCHINAZI, R.F.; BOUDINOT, F.D.; DOSHI, K.J.; MCCLURE, H.M. Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys. Antimicrob. Agents Chemother., v.34, p.1214-1219, 1990.
106. SMITH, R.V.; ROSAZZA, J.P. Microbial models of mammalian metabolism, aromatic hydroxylation. Arch. Biochem. Biophys., v.161, p.551-558, 1974.
107. SMITH, R.V.; ROSAZZA, J.P. Microbial models of mammalian metabolism. J. Pharm. Sci., v.11, p.1737-1758, 1975.
108. STEIGBIGEL, R.T.; COOPER, D.A.; KUMAR, P.N.; ERON, J.E.; SCHECHTER, M.; MARKOWITZ, M.; LOUTFY, M.R.; LENNOX, J.L.; GATELL, J.M.; ROCKSTROH, J.K.; KATLAMA, C.; YENI, P.; LAZZARIN, A.; CLOTET, B.; ZHAO, J.; CHEN, J.; RYAN, D.M.; RHODES, R.R.; KILLAR, J.A.; GILDE, L.R.; STROHMAIER, K.M.; MEIBOHM, A.R.; MILLER, M.D.; HAZUDA, D.J.; NESSLY, M.L.; DINUBILE, M.J.; ISAACS, R.D.; NGUYEN, B.Y.; TEPPLER, H. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med., v.359, p.339-354, 2008.
109. STJERNSCHANTZ, E.; VERMEULEN, N.P.E.; OOSTENBRINK C. Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450. Expert Opin. Drug Metab. Toxicol., v. 4, p.513-527, 2008.
110. TESTA, B.; BALMAT, A.L.; LONG, A.; JUDSON, P.N. Predicting drug metabolism - an evaluation of the expert system METEOR. Chem. Biodivers., v.2, p.872-885, 2005.
111. TRAPNELL, C.B.; KLECKER, R.W.; Jamis-Dow, C.; COLLINS, J.M. Glucuronidation of 3'-azido-3'- deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob. Agents Chemother., v.42, p.1592-1596, 1998.
112. TRÉLUYER, J.M.; BOWERS, G.; CAZALI, N.; SONNIER, M.; REY, E.; PONS, G.; CRESTEIL, T. Oxidative metabolism of amprenavir in the human liver. effect of the CYP3A maturation. Drug Metab. Dispos., v.31, p.275-281, 2003.
113. UNAIDS/WORLD HEALTH ORGANIZATION. Report on the global HIV/AIDS epidemic 2008. August 2008. Geneva: Joint United Nations Programme on HIV/AIDS, p.1-356, 2008.
114. VEAL, G.J.; BACK, D.J. Metabolism of zidovudine. Gen. Pharmacol., v.26, p.1469-1475, 1995.
115. VITORIA, M.; GRANICH, R.; GILKS, C.F.; GUNNEBERG, C.; HOSSEINI, M.; WERE, W.; RAVIGLIONE, M.; DE COCK, K.M. The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Am. J. Clin. Pathol., v.131, p.844-848, 2009.
116. VOORMAN, R.L.; MAIO, S.M.; HAUER, M.J.; SANDERS, P.E.; PAYNE, N.A.; ACKLAND, M.J. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. Drug Metab. Dispos., v.26, p.631-639, 1998a.
117. VOORMAN, R.L.; MAIO, S.M.; PAYNE, N.A.; ZHAO, Z.; KOEPLINGER, K.A.; WANG, X. Delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. J. Pharmacol. Exp. Ther., v.287, p.381-388, 1998b.
118. VOORMAN, R.L.; PAYNE, N.A.; WIENKERS, L.C.; HAUER, M.J.; SANDERS, P.E. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. Drug Metab. Dispos., v.29, p.41-47, 2001.
119. WALKER, D.K.; ABEL, S.; COMBY, P.; MUIRHEAD, G.J.; NEDDERMAN, A.N.; SMITH, D.A. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos., v.33, p.587-595, 2005.
120. WARD, B.A.; GORSKI, J.C.; JONES, D.R.; HALL, S.D.; FLOCKHART, D.A.; DESTA, Z. The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism. Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther., v.306, p.287-300, 2003.
121. WESTBY, M.; VAN DER RYST, E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antiviral Chem. Chemother., v.16, p.339-354, 2005.
122. WU, E.; SANDOVAL, T.; ZHANG, K.; GRETTENBERGER, H.; HEE, B.; LEE, C.; WEBBER, S.; SHETTY, B. Cytochrome P450 isoforms involved in the metabolism of nelfinavir mesylate, an HIV-1 protease inhibitor. In: INTERNATIONAL ISSX MEETING, 5., Cairns, Australia, 1998. Abstracts. Cairns: International Society for the Study of Xenobiotics, 1998. p.110-110.
123. YOSHITOMI, S.; IKEMOTO, K.; TAKAHASHI, J.; MIKI, H.; NAMBA, M.; ASAHI, S. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicol. In Vitro, v.15, p.245-256, 2001.
124. YU, X.; CUI, D.; DAVIS, M.R. Identification of in vitro metabolites of indinavir by "intelligent automated LC-MS/ MS" (INTAMS) utilizing triple quadrupole tandem mass spectrometry J. Am. Soc. Mass Spectrom., v.10, p.175-183, 1999.
125. ZHANG, K.; KERR, B.; HEE, B.; TALAAT, R.; MOGER, L.; SHETTY, B.; WEBBER, S. Biotransformation of nelfinavir, a potent HIV protease inhibitor, in healthy human subjects. In: INTERNATIONAL ISSX MEETING, 5., Cairns, Australia, 1998. Abstracts. Cairns: International Society for the Study of Xenobiotics, 1998. p.112-112.
126. ZHANG, K.E.; WU, E.; PATICK, A.K.; KERR, B.; ZORBAS, M.; LANKFORD, A.; KOBAYASHI, T.; MAEDA, Y.; SHETTY, B.; WEBBER, S. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob. Agents Chemother., v.45, p.1086-1093, 2001.
127. ZMIJEWSKI, M.; GILLESPIE, T.A.; JACKSON, D.A.; SCHMIDT, D.F.; YI, P.; KULANTHAIVEL, P. Application of biocatalysis to drug metabolism: preparation of mammalian metabolites of a biaryl-bis-sulfonamide AMPA receptor potentiator using actinoplanes missouriensis. Drug Metab. Dispos., v.34, p.925-931, 2006.